As expected, the European Commission (EC) approves Amgen (NASDAQ:AMGN) and development partner Allergan's (NYSE:AGN) MVASI, a biosimilar of Roche's (OTCQX:RHHBY) Avastin. The FDA approved it in September 2017.
Two months ago, the advisory group CHMP adopted a positive opinion backing approval.
The companies are collaborating on the development and commercialization of four oncology biosimilars. Amgen has 10 in its portfolio.
Previously: European advisory group backs Amgen's Avastin biosimilar ABP 215 (Nov. 10, 2017)
Subscribe for full text news in your inbox